Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in San Sebastian De Los Reyes – page 219

3 196 clinical trials in San Sebastian De Los Reyes, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
San Sebastian De Los Reyes at a glance
3 196
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 196 trials in San Sebastian De Los Reyes

Open in trial search

Hepatocellular carcinoma

Not recruiting

Study of Atezolizumab and Bevacizumab for Patients with High-Risk Hepatocellular Carcinoma After Surgery or Ablation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of Vutrisiran and Patisiran for Patients with Hereditary Transthyretin Amyloidosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Patisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Escherichia urinary tract infection

Not recruiting

Study of ExPEC9V vaccine for preventing invasive E.

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Janssen Vaccines & Prevention B.V.

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Ibrutinib and Rituximab for Patients with Indolent Mantle Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Fundacion Geltamo

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of CAEL-101 with Plasma Cell Dyscrasia Treatment in Patients with Stage IIIa AL Amyloidosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Alexion Pharmaceuticals Inc.

HER2 positive breast cancer

Not recruiting

Study on the Safety and Effects of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2-positive Metastatic Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Eosinophilic granulomatosis with polyangiitis

Not recruiting

Study on the Effectiveness and Safety of Depemokimab vs. Mepolizumab for Adults with Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Pancreatic carcinoma metastatic

Not recruiting

Study of Zolbetuximab with Nab-Paclitaxel and Gemcitabine for Adults with Metastatic Pancreatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Chronic myeloid leukaemia

Not recruiting

Study on Asciminib and Asciminib Hydrochloride for Patients with Chronic Myelogenous Leukemia in Chronic Phase After Two or More Tyrosine Kinase Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Asciminib
  • Sponsor:Novartis Pharma AG

Juvenile idiopathic arthritis

Not recruiting

Long-Term Study of Tofacitinib for Children and Teens with Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Tofacitinib
  • Sponsor:Pfizer Inc.

Parkinson's disease

Not recruiting

Study on the Safety and Effects of Afamelanotide for Patients with Early Parkinson's Disease

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Afamelanotide
  • Sponsor:Clinuvel Europe Limited

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in San Sebastian De Los Reyes

What the registry says about research in the country

01 Immunology & Allergies

Research focusing on innovative treatments for allergic rhinoconjunctivitis and immune system disorders. Studies include testing immunotherapy effectiveness using specific allergen proteins.

  • Allergic Rhinoconjunctivitis
  • Atopic Dermatitis
  • Myasthenia Gravis

Trials evaluate novel therapeutic approaches for autoimmune conditions and allergic responses.

02 Cardiovascular Health

Comprehensive studies addressing various cardiovascular conditions, including deep vein thrombosis and heart failure management.

  • Pulmonary Embolism
  • Atherosclerotic Disease
  • Hypercholesterolemia

Research focuses on innovative treatments and preventive approaches for cardiovascular complications.

03 Oncology Research

Advanced clinical trials investigating treatments for various cancer types, with emphasis on ovarian cancer and breast cancer therapies.

  • Epithelial Ovarian Cancer
  • HER2+ Breast Cancer
  • Endometrial Cancer

Studies evaluate targeted therapies and maintenance treatments for cancer patients.

04 Metabolic & Systemic Disorders

Research examining treatments for systemic lupus erythematosus and metabolic conditions affecting multiple body systems.

  • Obesity Management
  • Diabetic Neuropathy
  • Liver Disease

Trials focus on innovative therapeutic approaches for chronic systemic conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.